{"name":"Nasus Pharma","slug":"nasus-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Epinephrine Injection 0.3 mg","genericName":"Epinephrine Injection 0.3 mg","slug":"epinephrine-injection-0-3-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Epinephrine Injection 0.3 mg","genericName":"Epinephrine Injection 0.3 mg","slug":"epinephrine-injection-0-3-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSEZUWHhJaEV3a3FUMEl5WEhrN2NDN2tRdE1RRTdJekJjdjNaRUFUbDB3dVVZMVFJR0gxQVI2S21TdDNIeTJZRVlXcHgydEFVVW5iU2ZmOVIyWnEwaTBHWWlVRVlQUDd4MHgyNGlZT3BkOEdUNXpxdG5qSVFkOFh6NEFrQjlDcnNtS2lNSVByZDl5bmtRX0s4elBFcVRaSnRocjdwTXh0THVpRmVsVWpDSjlhb0RGY0RBM1pHMXo4cko?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX) - Stock Titan","headline":"Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPamU1ZEo1Q2Jqc3FDRWJhdTUwdXNXM0g4czZUQmNyOV9ZUm0wQWNQckt0WUNULU51UnBva0NhSVBIdzJlaHJRTHBtYlI4YlZXMHFiaDhCa2VkTUxlZVJTNWRjRUdEc1Ruek9HM1p3ZFRzRHdWc2RUMDJyb2g2M1V5ODhKZE5oczdCX3Z5VTl4N1ozWFl0dzB0RkJPZ2I?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"[EFFECT] Nasus Pharma Ltd SEC Filing - Stock Titan","headline":"[EFFECT] Nasus Pharma Ltd SEC Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNZ1F1dmh1cDBZWG0zQkdwQVBUZ0Ezc2xUTzM5TTBvZ1NPMU80QUVvRWFqSG5IcWdjNEU4TDNtQkdVdERiSi12cXBwZUFnS1F0NXk3RUNfb0lYN0pLZmk0VDFoWV80VmJqbUpVMnl2aGcwdzgyQ0dKNXc2aVVqZnNwaTlob0ZnZ2NUbDVsaUlSM2VVQjM5WjFmTVk4N2V0c3ZTeHpLZGFrTXYyR21FSlhMZTNpdnRWd2xnQU1Raw?oc=5","date":"2026-03-31","type":"trial","source":"Barchart.com","summary":"Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up? - Barchart.com","headline":"Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQVlVRNjJDaHM0Q3VEbkZvbWhJN1VjLU54M2w3bEczajhSeXRsWGx2V2ZuSmNRVENxUTEweEZnaEkxUk1oMUpBaXNMazhsbUY3NktuUHl2VThaTTlhVnNyTWNOaXJUaHEtdi1UeUtMS3NuYXFIN3RqekF0ZnRNRG0tSXJGbGhGNU0yaGxBMnlTWjVwWHVlMHFZSm00YUVBZGUyRzR2NGRPUzN0akFwQ2I0MlBuYW1pTVl6aUhfdg?oc=5","date":"2026-03-25","type":"trial","source":"Investing.com","summary":"Nasus Pharma reports Phase 2 results for intranasal epinephrine - Investing.com","headline":"Nasus Pharma reports Phase 2 results for intranasal epinephrine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNakVnbE4tX0c5Wm1qMDZIQzZIakhOTUwyRVowZldaUWdFNDlrd0FISDdvQ0NrT3NOQ2lfY2NKVEdDb3paQTJ3RGNIRFVaQWU1WkNjQjUtVWE5WlVLeGN5Ym9JZXBUbEYwcmhzRGpGQk9nb1VmZE9YYzFHeEFwVDFPWk9UWUUzeEhibDEyV0M2dVdiRHUxMHBuOFlscjF4bUdieDIxNlEzTQ?oc=5","date":"2026-03-25","type":"trial","source":"Yahoo Finance","summary":"Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Yahoo Finance","headline":"Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Busine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPMTRySVFDYkJWSnkwMEhwejJpRlNfdkM0aGRrYXR6SWpCNHVRRmlFQ05EcHRpLTJ2bzJaQWxIekoxUm13amRpX3hlcl9wRWFLZlZnei0wZWtmSzBnU01ETzFFVWFWbVhVQUFNVlhRekY5TXFZbFVWeHRpenpud3V0TVlIU1M1c2lqQjduMzkwa0tHMUJTTVFkRXozSkprd3N3VE9WT3l3N3FKbWdLRDVMMlJB?oc=5","date":"2026-03-25","type":"trial","source":"Stock Titan","summary":"Nasus Pharma (NSRX) touts NS002 Phase 2 data and cash runway - Stock Titan","headline":"Nasus Pharma (NSRX) touts NS002 Phase 2 data and cash runway","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZ3JjZHBVaWVDMkg0ZEVZUEQ0YnVBZW1mWG1VV2Y0N1QwSHdnbGphdXZJX2FCekVRRzJ4aUp4WkFVX3djODRDZHROOGd3UFlLNTc5eVprWmpqeExLVURUWUU5YkFpYnpVOTJmS25oV1VRRWhxLVJxUVdLY1BkbkdIUEplRkhfS044RF9wTkFCYVk1Y3BSU0tpWDNCZjlGQUZHdi1obktrdVRCaHNWWmUzQ0JKSjA3aHNoUTBIRklLakQ?oc=5","date":"2026-03-25","type":"trial","source":"Stock Titan","summary":"Nasal epinephrine showed faster absorption than EpiPen; pivotal study next - Stock Titan","headline":"Nasal epinephrine showed faster absorption than EpiPen; pivotal study next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNLTVqZE10UnA0SGlxYnVPemhkc0xMZk1Ub2ZqWG1GWERkYjk3c21IM2I3VTRKTm1CYU1QMjEyaVBiUkU4eTVINXFrcXBfZHdhS2RVOV9LcXNWSXVsaHlSOF9RczBaOHdHQ29ITWlaMDhTaUwyZ2ViMThOeWE4bkMyd0lYSUNWZ05t?oc=5","date":"2026-03-16","type":"trial","source":"Yahoo Finance","summary":"Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therap","headline":"Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPZ0NpLTlvSTdqRzFEeUdHNHlKSC1zYmtCcWc4UkFzVEZDaHVMOXFPc2xKOUhjQXNkN3NYNURicHFmQWxVT21ibGV6R0pZS3ZfSzNTTklGWGJmemVDVTJBYlJpZzg1eWtVbFhfSEdDU05fVGFKaWltcF84ZUE2bHBUUHBSdXcxNC1sczFSOENHek1mRml3RlZxd2NrZTk2dkc5NXEyaEVDVzE3MER6ZlpURlZSZGdrc1Y4LWtqdHpPUQ?oc=5","date":"2026-03-16","type":"trial","source":"Investing.com","summary":"Nasus Pharma reports faster epinephrine delivery in Phase 2 study - Investing.com","headline":"Nasus Pharma reports faster epinephrine delivery in Phase 2 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNGRpaFU3OEE0N1duaVIydUM1ZzNoUFFvOHlIZTV0WExDSjhQRE1yMzhHSk9faXhydXpZck04N1Fsb3VENllYZWxtU2N3VEVad2V4cDJOUXlRa3YyYUdjU1cxMTNWRHZZYnAzMHQxLWRhSDVpeHJndUJ0eGRHTTlvNjdnZTlXNlVTbTB3?oc=5","date":"2026-03-09","type":"trial","source":"Yahoo Finance","summary":"Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study - Yahoo Finance","headline":"Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNbktHVGFRQV95ZmJzTGVQM2t0MzRDTEx1THJ0eVQ3N2R4LVJJb2t0ZjNJaTFmSHRHN0w5VE5lYS12WlRFMkVYMFViRUkyT0FIMjdNOHdIQmpsT2hwS2xTY01IdmlVWlJUNmN0NEFSWU1ISmRvYmdUYTFGMVUyVGp0eGx2MUstTVZNM1NVM2hzRkhyZVNVQjVCYlFwQ1pJU2k2cG0tT1ZYVmdSaW9Ea0JVMFJIR2MwUVFaOF9teVNabTI0NHBxT193NFdMRjIzNE5CWk1VNHZ3ekRoMEJMWEtIU2RjbXpuVkp0QVVvYg?oc=5","date":"2026-03-09","type":"pipeline","source":"GlobeNewswire","summary":"Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum - GlobeNewswire","headline":"Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPT3pYQjFwZHdjdHYzcXZlVmVqN3RYSEQxU0FhNEkydFlucjNQWHBKNnRkcklmV3BvOHpjQ2I2N1ZhR2JHSlJhSVZVTWVfcHZfUmh1dFRUWWFPNHVfb2J2WjFLcDVCbDd1ZDJGXzFDRVh2VkphSElnSXBJUFRtS25McjMwRFdkamNNZEtkQUZFMkZla0ozV1UybG9jbVBpU2Q1WG5PWDRvazJweFduQXpfLUFadFZ5QktmRGdLRGdBMGp0UUJrYUxfMVFGM1YyTGZTS1E?oc=5","date":"2026-02-10","type":"pipeline","source":"GlobeNewswire","summary":"Nasus Pharma Announces Pricing of $15.0 Million Private Placement - GlobeNewswire","headline":"Nasus Pharma Announces Pricing of $15.0 Million Private Placement","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}